1
|
Borisov A, Khan M, Mudaliar S, Chakrabarti S, Collins D, Shaipanich T, Wilson D, Ignaszewski A, Toma M. CLINICAL CHARACTERISTICS OF PATIENTS WITH SUSPECTED AND CONFIRMED CARDIAC SARCOIDOSIS REFERRED TO A SPECIALIZED CLINIC. Can J Cardiol 2020. [DOI: 10.1016/j.cjca.2020.07.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
2
|
Tam A, Hughes M, McNagny KM, Obeidat M, Hackett TL, Leung JM, Shaipanich T, Dorscheid DR, Singhera GK, Yang CWT, Paré PD, Hogg JC, Nickle D, Sin DD. Hedgehog signaling in the airway epithelium of patients with chronic obstructive pulmonary disease. Sci Rep 2019; 9:3353. [PMID: 30833624 PMCID: PMC6399332 DOI: 10.1038/s41598-019-40045-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 01/21/2019] [Indexed: 01/21/2023] Open
Abstract
Genome-wide association studies have linked gene variants of the receptor patched homolog 1 (PTCH1) with chronic obstructive pulmonary disease (COPD). However, its biological role in the disease is unclear. Our objective was to determine the expression pattern and biological role of PTCH1 in the lungs of patients with COPD. Airway epithelial-specific PTCH1 protein expression and epithelial morphology were assessed in lung tissues of control and COPD patients. PTCH1 mRNA expression was measured in bronchial epithelial cells obtained from individuals with and without COPD. The effects of PTCH1 siRNA knockdown on epithelial repair and mucous expression were evaluated using human epithelial cell lines. Ptch1+/− mice were used to assess the effect of decreased PTCH1 on mucous expression and airway epithelial phenotypes. Airway epithelial-specific PTCH1 protein expression was significantly increased in subjects with COPD compared to controls, and its expression was associated with total airway epithelial cell count and thickness. PTCH1 knockdown attenuated wound closure and mucous expression in airway epithelial cell lines. Ptch1+/− mice had reduced mucous expression compared to wildtype mice following mucous induction. PTCH1 protein is up-regulated in COPD airway epithelium and may upregulate mucous expression. PTCH1 provides a novel target to reduce chronic bronchitis in COPD patients.
Collapse
Affiliation(s)
- A Tam
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - M Hughes
- Biomedical Research Centre (BRC), University of British Columbia, Vancouver, British Columbia, Canada
| | - K M McNagny
- Biomedical Research Centre (BRC), University of British Columbia, Vancouver, British Columbia, Canada
| | - M Obeidat
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - T L Hackett
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.,Department of Anaesthesiology, Pharmacology, & Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
| | - J M Leung
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - T Shaipanich
- Division of Respiratory Medicine, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
| | - D R Dorscheid
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - G K Singhera
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - C W T Yang
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - P D Paré
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - J C Hogg
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - D Nickle
- Merck & Co. Inc., Rahway, New Jersey, United States of America
| | - D D Sin
- Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.
| |
Collapse
|
3
|
Kiamanesh O, Nazzari H, Shaipanich T, Collins D, Chakrabarti S, Wilson D, Ignaszewski A, Toma M. UTILIZATION OF PET IMAGING IN PATIENTS REFERRED TO SPECIALIZED CARDIAC SARCOIDOSIS CLINIC. Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Smoragiewicz M, Laskin J, Wilson D, Ramsden K, Yee J, Lam S, Shaipanich T, Zhai Y, Ho C. Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review. ACTA ACUST UNITED AC 2014; 21:e768-74. [PMID: 25489265 DOI: 10.3747/co.21.2125] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND Combined positron-emission tomography and computed tomography (pet-ct) reduces futile thoracotomy (ft) rates in patients with non-small-cell lung cancer (nsclc). We sought to identify preoperative risk factors for ft in patients staged with pet-ct. METHODS We retrospectively reviewed all patients referred to the BC Cancer Agency during 2009-2010 who underwent pet-ct and thoracotomy for nsclc. Patients with clinical N2 disease were excluded. An ft was defined as any of a benign lesion; an exploratory thoracotomy; pathologic N2 or N3, stage iiib or iv, or inoperable T3 or T4 disease; and recurrence or death within 1 year of surgery. RESULTS Of the 108 patients who met the inclusion criteria, ft occurred in 27. The main reason for ft was recurrence within 1 year (14 patients) and pathologic N2 disease (10 patients). On multivariate analysis, an Eastern Cooperative Oncology Group performance status greater than 1, a pet-ct positive N1 status, a primary tumour larger than 3 cm, and a period of more than 16 weeks from pet-ct to surgery were associated with ft. N2 disease that had been negative on pet-ct occurred in 21% of patients with a pet-ct positive N1 status and in 20% of patients with tumours larger than 3 cm and non-biopsy mediastinal staging only. The combination of pet-ct positive N1 status and a primary larger than 3 cm had 85% specificity, and the presence of either risk factor had 100% sensitivity, for ft attributable to N2 disease. CONCLUSIONS To reduce ft attributable to N2 disease, tissue biopsy for mediastinal staging should be considered for patients with pet-ct positive N1 status and with tumours larger than 3 cm even with a pet-ct negative mediastinum.
Collapse
Affiliation(s)
| | - J Laskin
- British Columbia Cancer Agency, Vancouver, BC
| | - D Wilson
- British Columbia Cancer Agency, Vancouver, BC
| | - K Ramsden
- British Columbia Cancer Agency, Vancouver, BC
| | - J Yee
- Vancouver General Hospital, Vancouver, BC
| | - S Lam
- British Columbia Cancer Agency, Vancouver, BC
| | | | - Y Zhai
- Department of Statistics, University of British Columbia, Vancouver, BC
| | - C Ho
- British Columbia Cancer Agency, Vancouver, BC
| |
Collapse
|
10
|
Shaipanich T, Cianciolo GJ. The rapid and large scale separation of peritoneal macrophages. Immunology 1972; 22:525-9. [PMID: 4622703 PMCID: PMC1407822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
A simple method for rapid and large scale (over 109 cells) separation of peritoneal macrophages by incubation in a glass-bead column and elution with buffered ethylenediamine tetraacetic acid (EDTA) solution is described. Macrophages obtained were about 90 per cent pure with the recovery rates of 38–53 per cent depending upon the sample size, and 83 per cent viability. Lymphocyte contamination was reduced to 5 per cent or less.
Collapse
|